Pitvarfibrilláció: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R00

  Emotional and biobehavioral mechanisms of parent-infant emotional synchrony

  Children's Hosp of Philadelphia· Philadelphia, Egyesült Államok· 248 999 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, Egyesült Államok· 40 326 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NINR · R01

  SCH: Integrated AI and Sensing Systems for Mitigating Heart Failure Readmissions in High-Risk Groups with Obesity

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 1 200 000 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NIA · R43

  A Smart Remote Monitoring System for Cardiometabolic Management in Patients with Alzheimer's and Related Dementia

  Aventusoft, Llc· Boca Raton, Egyesült Államok· 500 000 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NINDS · R56

  Characterizing a Calcium Channel Causing FASP: Examining Entrainment Changes as a Mechanism for Phase Advance

  University of California, San Francisco· San Francisco, Egyesült Államok· 574 000 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2029. aug.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Svédország· EU contribution 252 180 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spanyolország· EU contribution 209 915 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 292 119 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Izrael· EU contribution 3 375 000 EUR· until 2031. dec.

10 of 783 running projects, newest first. Listed amounts together: 464,1 M USD + 148,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

  NCT04885634· Axel Brandes· Frissítve: 2023. nov. 3.

  “Not received funding.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

  NCT07715929· Yunlong Wang· Forrás

• Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

  NCT07630454· Yunlong Wang· Forrás

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 222
• Genome-Wide Association Study 62

• Untargeted Metabolomic Analysis of Acute Kidney Injury After Maze-Inclusive Cardiac Surgery.

  J Korean Med Sci, 2026. nov.

• Large-scale plasma metabolic profiling identifies signatures and biomarkers associated with air pollution and arrhythmias: A prospective cohort study from UK Biobank.

  Ecotoxicol Environ Saf, 2026. okt.

• Metabolic Signatures of Atrial Functional Impairment in Paroxysmal Atrial Fibrillation Patients: A CMR Strain-metabolomics Study.

  J Cardiovasc Transl Res, 2026. aug.

• Targeted metabolomic profiling and machine learning-based prediction models for persistent atrial fibrillation: a multi-center observational study.

  PeerJ, 2026. aug.

• Phenotypic Characterization of Unclassified Pulmonary Hypertension.

  Circ Heart Fail, 2026. jún.

• Multi-omic biomarkers in cardiovascular disease: Discovery to clinical translation.

  Clin Chim Acta, 2026. jún.

• Metabolomic and Genomic Insights Into Adverse Events in Paroxysmal Atrial Tachycardia.

  Biomed Chromatogr, 2026. ápr.

• Identification of metabolic biomarkers in atrial fibrillation patients via the multi-omics strategy: the critical involvement of pyruvate kinase M2.

  Arch Biochem Biophys, 2026. márc.

• Circulating cardiometabolic metabolite profiles associated with ambient air pollution and atrial fibrillation risk: a prospective cohort study.

  Cardiovasc Diabetol, 2026. márc.

• Utilization of Serum Metabolomics and Polygenic Risk Scores in a Novel Risk Stratification Tool for the Prediction of Incident Atrial Fibrillation.

  Circ Arrhythm Electrophysiol, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.